What is the clinical evidence from this study?

Study design: Editorial. Population: Heart failure. Intervention: Trimetazidine.

What question did this study set out to answer?

To evaluate the biochemical and mitochondrial mechanisms by which trimetazidine and related metabolic therapies improve myocardial energetics and function in heart failure.

August 30, 2026European Heart JournalOpen Access

Metabolic therapy for heart failure

View Full Paper

Ask AI

Bookmark

Key result

Trimetazidine may improve heart failure by reducing free fatty acid-induced mitochondrial uncoupling, highlighting the need for large clinical trials to evaluate its effect on mortality.

Design

Editorial

Authors

MEM. Faadiel EssopGeneral / Preventive / Lipids LOLionel H. OpieGeneral Cardiology

Discussion

Member takes

Implication

Metabolic therapies such as trimetazidine may improve cardiac mechanical efficiency in heart failure by reducing free fatty acid-induced mitochondrial uncoupling.

Key Points

To evaluate the biochemical and mitochondrial mechanisms by which trimetazidine and related metabolic therapies improve myocardial energetics and function in heart failure.
Synthesized mechanistic and clinical evidence evaluating fatty acid oxidation inhibitors, including trimetazidine and ranolazine, in ischemic and failing myocardium.
Analyzed mitochondrial bioenergetics, focusing on proton leak, uncoupling protein (UCP2/3) activation, and the shift from fatty acid oxidation to glucose utilization.
Excess circulating free fatty acids induce mitochondrial uncoupling and oxygen wastage, reducing the efficiency of cardiac ATP generation during heart failure.
Partial inhibition of fatty acid beta-oxidation by trimetazidine enhances glucose oxidation and preserves membrane-protective glycolytic ATP.
Trimetazidine protects cardiac function by mitigating mitochondrial uncoupling, suppressing reactive oxygen species generation, and preventing mitochondrial permeability transition pore opening.

PICO

Population

Heart failure

Intervention / Comparator

Trimetazidine

Metabolic therapies such as trimetazidine may improve cardiac mechanical efficiency in heart failure by reducing free fatty acid-induced mitochondrial uncoupling.

Limitations

Direct proof that TMZ decreases activation of myocardial uncoupling proteins via depressed fatty acid oxidation is still outstanding
Lack of experimental data measuring oxygen uptake of the normal beating heart before and after TMZ or ranolazine

Cite This Study

Essop et al. (2004) conducted an editorial in Heart failure. Trimetazidine was evaluated. Trimetazidine may improve heart failure by reducing free fatty acid-induced mitochondrial uncoupling, highlighting the need for large clinical trials to evaluate its effect on mortality.

synapsesocial.com/papers/6a93a11e7e87dd57ba101418 https://doi.org/10.1016/j.ehj.2004.08.019

Topics

Heart failure HFrEF treatment

View Full Paper

Ask AI

Bookmark

Implication

Metabolic therapies such as trimetazidine may improve cardiac mechanical efficiency in heart failure by reducing free fatty acid-induced mitochondrial uncoupling.

Metabolic therapy for heart failure

Discussion

Member takes

Implication

Key Points

PICO

Limitations

Cite This Study

Topics

Metabolic therapy for heart failure

Discussion

Member takes

Implication

Key Points

PICO

Limitations

Cite This Study

Also Consider

Topics

Also Consider